bluebird bio Inc at Goldman Sachs Healthcare CEOs Unscripted: A View from the Top Transcript
Good afternoon, everyone. Thanks for joining us. I'm Salveen Richter, I cover the biotechnology sector on Goldman Sachs, and we're very pleased to have the CEO or Chief
(technical difficulty)
of bluebird with us, Nick Leschly.
Questions & Answers
So Nick, you have with us the evolution of bluebird over the last decade, and the company is a pioneer in the field of genomic medicine. So how does the company and industry today compare to your 10-year view from when you first started as CEO?
Well, first, thanks, Salveen, for having me here. I appreciate it. And you're always good about asking questions that I'm not prepared to answer. So 10 years, long time. I tend to measure that. And now my kids are leaving me, going to college and things like that. So it's been a big run in that
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |